Evidence map›Paper›PMID 42252624›Full record

ArticleAmerican journal of hematology2026

Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.

Xianggui Yuan, Qian Luo, Yurong Huang, Chaoyi Li, Teng Yu, Shanshan Guo, Qunyi Guo, Xueli Jin, Jiefeng Tong, Aiqi Zhao and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xianggui YuanDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qian LuoDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yurong HuangDepartment of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chaoyi LiSchool of Science, Zhejiang University of Science and Technology, Hangzhou, China.
Teng YuDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shanshan GuoDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qunyi GuoDepartment of Hematology, Taizhou Hospital of Zhejiang Province, Taizhou, China.
Xueli JinDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiefeng TongDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Aiqi ZhaoDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wen LeiDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xian LiDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0001-6380-7336
Baizhou LiDepartment of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shumei WeiDepartment of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wenbin QianDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-9817-6674
Yun LiangDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

National Natural Science Foundation of China 82350104National Natural Science Foundation of China 82400217Natural Science Foundation of Zhejiang Province of China BY24ZH080013Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0501300
6 · The paper itself

Abstract

Current prognostic models fail to capture the biological complexity of primary central nervous system lymphoma (PCNSL). We integrated whole-genome sequencing and multiplex immunofluorescence in 68 treatment-naïve patients to define four genomic subtypes (C1, C2, C3, and C4) with divergent survival (C4 worst: median overall survival [OS], 26 months). In parallel, a novel tumor microenvironment (TME) classification based on CD8

Indexed as

Central Nervous System NeoplasmsLymphomaTumor MicroenvironmentAdultAgedFemaleGenomicsHumansMaleMiddle AgedPrognosisRisk AssessmentWhole Genome SequencingCD8+T/M2 ratiogenomic subtypesprimary central nervous system lymphomaprognostic stratificationtumor microenvironment

Identifiers

PMID42252624
PMCPMC13544481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.